These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19894139)

  • 1. Developing a consumer reporting program in Malaysia: a novel initiative to improve pharmacovigilance.
    Palaian S; Alshakka M; Mohamed Izham
    Pharm World Sci; 2010 Feb; 32(1):2-6. PubMed ID: 19894139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.
    Härmark L; van Hunsel F; Grundmark B
    Drug Saf; 2015 Apr; 38(4):337-47. PubMed ID: 25627832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do Health Professionals have Positive Perception Towards Consumer Reporting of Adverse Drug Reactions?
    Alshakka MA; Ibrahim MI; Hassali MA
    J Clin Diagn Res; 2013 Oct; 7(10):2181-5. PubMed ID: 24298470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 5. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
    Matos C; van Hunsel F; Joaquim J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Evaluation of Indian Consumers' Reporting of Suspected Adverse Drug Reactions with a Designated Reporting Form.
    Rehan HS; Sah R; Gupta A; Nagar P
    Curr Drug Saf; 2017; 12(1):51-56. PubMed ID: 27188794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrénées region (PharmacoMIP) network 2-year pilot study.
    Gony M; Badie K; Sommet A; Jacquot J; Baudrin D; Gauthier P; Montastruc JL; Bagheri H
    Drug Saf; 2010 May; 33(5):409-16. PubMed ID: 20397740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance activities in Nepal.
    Palaian S; Mohamed Ibrahim MI; Mishra P; Alam K; Shankar PR; Thapa BB
    Drug Saf; 2010 Oct; 33(10):889-90. PubMed ID: 20812773
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient Reporting of Adverse Drug Reactions (ADRs): Survey of Public Awareness and Predictors of Confidence to Report.
    Hariraj V; Aziz Z
    Ther Innov Regul Sci; 2018 Nov; 52(6):757-763. PubMed ID: 29714567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association.
    Vilhelmsson A; Svensson T; Meeuwisse A; Carlsten A
    BMC Pharmacol Toxicol; 2012 Dec; 13():19. PubMed ID: 23259410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse drug reaction surveillance system in Korea].
    Choi NK; Park BJ
    J Prev Med Public Health; 2007 Jul; 40(4):278-84. PubMed ID: 17693730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The monitoring medicines project: a multinational pharmacovigilance and public health project.
    Pal SN; Olsson S; Brown EG
    Drug Saf; 2015 Apr; 38(4):319-28. PubMed ID: 25829215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A computerized database for adverse drug reactions: strengthening a hospital-based pharmacovigilance programme in India.
    Jose J; Jimmy B; Rao PG
    Drug Saf; 2008; 31(12):1063-7. PubMed ID: 19026024
    [No Abstract]   [Full Text] [Related]  

  • 18. Reporting of fatal adverse drug reactions.
    Liu BA; Knowles SR; Mittmann N; Einarson T; Shear NH
    Can J Clin Pharmacol; 2001; 8(2):84-8. PubMed ID: 11493936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive intervention for adverse drug reactions identification and reporting in a Pediatric Emergency Department.
    Morales Ríos O; Jasso Gutiérrez L; Talavera JO; Téllez-Rojo MM; Olivar López V; Garduño Espinosa J; Muñoz Hernández O
    Int J Clin Pharm; 2016 Feb; 38(1):80-7. PubMed ID: 26499501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.